Luye Pharma Group Ltd.
LYPHF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $7,221 | $9,437 | $10,116 | $11,434 |
| - Cash | $6,936 | $4,937 | $3,340 | $5,655 |
| + Debt | $11,871 | $10,321 | $9,453 | $8,424 |
| Enterprise Value | $12,156 | $14,820 | $16,230 | $14,203 |
| Revenue | $3,181 | $2,987 | $3,075 | $3,239 |
| % Growth | 6.5% | -2.9% | -5.1% | – |
| Gross Profit | $2,158 | $1,966 | $2,079 | $2,261 |
| % Margin | 67.8% | 65.8% | 67.6% | 69.8% |
| EBITDA | $1,004 | $1,252 | $939 | $1,029 |
| % Margin | 31.5% | 41.9% | 30.6% | 31.8% |
| Net Income | $313 | $84 | $388 | $383 |
| % Margin | 9.8% | 2.8% | 12.6% | 11.8% |
| EPS Diluted | 0.083 | -0.083 | 0.1 | 0.102 |
| % Growth | 200.8% | -182.5% | -1.8% | – |
| Operating Cash Flow | $1,784 | $562 | -$394 | $906 |
| Capital Expenditures | $0 | -$1,708 | $0 | -$633 |
| Free Cash Flow | $1,784 | -$1,146 | -$394 | $273 |